News round-up for 27-31 July by Megan Thomas, Content Team at DDW. 

This week’s news roundup centres around investment, innovation and strategic growth, which have dominated this week’s headlines. Across the drug discovery sector, companies have secured funding, expanded R&D capabilities and accelerated the adoption of AI-driven technologies. In addition, DDW has announced the preliminary speaker lineup for the Drug Discovery Innovators & Investors (DDII) Digital Forum.

The top stories: 

Drug Discovery Innovators & Investors Digital Forum announces speaker lineup

We are pleased to announce the preliminary speaker lineup for the Drug Discovery Innovators & Investors (DDII) Digital Forum, taking place 30 September 2026. Supported by DDW, the forum brings together senior leaders from biotech, pharma, academia, and investment to explore the opportunities and challenges shaping early-stage drug discovery.

Read more…

Qureight closes $20 million Series B financing

Cambridge data analytics company Qureight has raised $20 million in a Series B financing, led by Molten Ventures, which will support expansion of the Company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases.

Read more… 

Carterra at centre of US$7bn antibody discovery market

In a report published on July 16 2026, titled Lab-in-the-Loop: AI Rewires Antibody Discovery, Unlocking a US$7 billion LST Opportunity, “Lab-in-the-Loop” (LitL) is described as an emerging approach in which AI models propose candidate antibody sequences, wet lab experiments test them, and the resulting data is fed back into the AI to improve the next round of designs. This transforms what was once a slow, serial discovery process into a faster, guided one.

Read more… 

GSK plans new flagship R&D centre and £400m investment in UK

GSK has announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline.

Read more… 

New index reveals Eli Lilly as the top ranked company

Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.

Read more…